Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis — RAPAMI  

Inclusion Body Myositis (IBM) Clinical Trial

Official title: Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"

Status Completed

Clinical Trial Summary

Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease.

Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T regulatory cells and induces autophagy (protein degradation), all parameters impaired during IBM.

RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial evaluating rapamycine against placebo.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Inclusion Body Myositis (IBM)
• Myositis
• Myositis, Inclusion Body

• NCT number: NCT02481453
• Study type: Interventional
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 15, 2015
• Completion date: January 22, 2018